Myriad Genetics Reports Fiscal First-Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Myriad Genetics (MYGN) Misses Q1 EPS by 24c; Lowers Outlook
November 4, 2019 4:16 PM ESTMyriad Genetics (NASDAQ: MYGN) reported Q1 EPS of $0.08, $0.24 worse than the analyst estimate of $0.32. Revenue for the quarter came in at $186.3 million versus the consensus estimate of $202.1 million.
"We had a challenging start to fiscal year 2020 as hereditary cancer revenue accrual from small payers was impacted by the... More
